Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
← catalyst calendarSponsored by Amylyx Pharmaceuticals Inc. (industry) · AMLX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
664actual
Sites
69
Countries
Belgium, France, Germany +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-28 | actual | When the study began enrolling |
| Primary completion | 2024-01-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Amyotrophic Lateral Sclerosis
Interventions
- Other: Placebo
- Drug: AMX0035
Primary outcome
what the primary-completion date above is the date OFAmyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change
measured 48 weeks
Permalink · AMLX's whole pipeline · Catalyst calendar · Every registered study · What changed